Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Study Classification

INTERVENTIONAL

Study Start Date

1994-12-31

Study Completion Date

2000-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: The Epstein Barr virus can cause cancer and lymphoproliferative disorders. Ganciclovir is an antiviral drug that acts against the Epstein Barr virus. Arginine butyrate may make virus cells more sensitive to ganciclovir. Combining ganciclovir and arginine butyrate may kill more Epstein Barr virus cells and tumor cells.

PURPOSE: Phase I trial to study the effectiveness of arginine butyrate plus ganciclovir in treating patients who have cancer or lymphoproliferative disorders that are associated with the Epstein Barr virus.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies

NCT00917826

EBV Lymphomas Lympho-proliferative Diseases

TERMINATED PHASE2

Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)

NCT00002026

Leukoplakia, Hairy HIV Infections

COMPLETED NA

Effects of Long-Term Treatment With Valaciclovir (Valtrex) on Epstein-Barr Virus

NCT00005924

Epstein Barr Virus Infection Healthy

COMPLETED

Activity of Valomaciclovir in Infectious Mononucleosis Due to Primary Epstein-Barr Virus Infection

NCT00575185

Infectious Mononucleosis

COMPLETED PHASE1/PHASE2

Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies

NCT03397706

Epstein-Barr Virus-Associated Lymphoma Lymphoproliferative Disorders

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

* Determine the safety, toxicity, and the reversibility of toxicity of arginine butyrate in patients with Epstein Barr virus-induced malignancies or lymphoproliferative disorders.
* Determine the clinical pharmacology of arginine butyrate when administered with ganciclovir, including plasma half life and major routes of elimination in these patients.
* Determine the biologic effects of arginine butyrate in terms of inducing sensitivity to ganciclovir in tissue samples from selected patients.
* Determine the antitumor activity of this treatment regimen in these patients.

OUTLINE: Patients receive ganciclovir IV over 1 hour twice a day on days -1 to 21 for the first course (days 0-21 for all subsequent courses) and escalating doses of arginine butyrate IV continuously on days 0-21. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.

Patients are followed for a minimum of 42 days.

PROJECTED ACCRUAL: Approximately 20 patients will be accrued for this study within 2 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Leukemia Lymphoma Precancerous Condition Small Intestine Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

arginine butyrate

Intervention Type DRUG

ganciclovir

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Histologically confirmed malignancy or lymphoproliferative disease including the following:

* Nasopharyngeal carcinoma
* Hodgkin's lymphoma
* African Burkitt's lymphoma
* T-cell non-Hodgkin's lymphoma
* B-cell non-Hodgkin's lymphoma if Epstein Barr Virus (EBV) positive
* Other lymphomas associated with immunodeficiency or immunosuppression, including AIDS-related lymphoma
* B-cell lymphoproliferative disorders
* Monoclonal or oligoclonal B-cell lymphoid disease (no polyclonal disease)
* EBV positive by immunohistochemistry or in situ hybridization

* Negative serology for EBV allowed

PATIENT CHARACTERISTICS:

Age:

* 3 and over

Performance status:

* Any status

Hematopoietic:

* Absolute granulocyte count at least 1,000/mm\^3
* Platelet count at least 50,000/mm\^3

Hepatic:

* Bilirubin no greater than 1.5 mg/dL
* Aminotransferase less than 2 times normal

Renal:

* Creatinine less than 3.0 mg/dL
* Creatinine clearance greater than 30 mL/min

Cardiovascular:

* No acute myocardial infarction within the past 6 months
* No atrial fibrillation within the past 6 months

Other:

* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

* Prior bone marrow or stem cell transplantation allowed
* No concurrent immunotherapy
* No concurrent interferon or tacrolimus

Chemotherapy:

* At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin) and recovered
* No concurrent cytotoxic chemotherapy

Endocrine therapy:

* No concurrent steroids

Radiotherapy:

* Recovered from prior radiotherapy

Surgery:

* Not specified

Minimum Eligible Age

3 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No